कंपनी का अवलोकन
Intelligent Bio Solutions Inc. operates as a medical technology firm dedicated to the development and delivery of non-invasive testing and screening solutions across key international markets including Asia Pacific, the United States, the United Kingdom, and other global regions. The company's core operational focus is on providing intelligent fingerprinting drug screening systems, which represent its primary platform for delivering diagnostic capabilities to healthcare providers and institutions. Within the broader financial landscape, INBS functions specifically within the Healthcare sector and the specialized Medical Devices industry, positioning itself as a niche player in diagnostic instrumentation. The enterprise currently maintains a market capitalization of $5.10M, generates annual revenue of $3.58M, and employs a workforce of 53 individuals. These valuation and revenue figures indicate that the company is a small-cap entity with a limited market footprint, suggesting that its financial performance is highly sensitive to fluctuations in specific regulatory environments and adoption rates for its fingerprinting technology within the targeted geographic regions.
वित्तीय स्वास्थ्य
The company reported a revenue of $3.58M for the trailing twelve months, yet recorded a net income of $-11,294,226 and an EBITDA of $-9,836,561, revealing a significant structural gap where operational expenses substantially exceed total revenue generation. This disparity highlights a cost structure characterized by high overhead or heavy research and development expenditures that are not yet covered by current sales volumes, resulting in a substantial loss for every dollar of revenue earned. Free cash flow stands at $-14,541,733, which indicates a negative cash generation from operations and investing activities, implying that the company is currently burning cash reserves to fund its operations or growth initiatives rather than generating liquidity for shareholders. The gross margin is reported at 46.2%, suggesting that the company retains a healthy portion of revenue after direct costs of goods sold, whereas the operating margin of -290.9% and profit margin of 0.0% demonstrate severe inefficiencies in managing fixed costs and overall profitability relative to sales. On the balance sheet, the company holds $740,371 in cash against $1.92M in debt, resulting in a debt-to-equity ratio of 17.67, which signifies a highly leveraged financial position where debt obligations significantly outweigh equity capitalization. The current ratio of 2.38 suggests that the company possesses more than double the liquid assets required to cover its short-term liabilities, indicating a theoretically strong short-term liquidity position despite the leverage. Furthermore, the return on equity is -150.2% and the return on assets is -51.2%, metrics that reveal that management is currently destroying value for shareholders and failing to generate returns on the capital base employed in the business.
मूल्यांकन आकलन
Valuation metrics for Intelligent Bio Solutions Inc. present a complex picture due to the absence of traditional profitability ratios, as the P/E Ratio (TTM) is listed as N/A, while the forward P/E is 7.29, implying that the market prices the stock based on expected future earnings rather than historical performance. The price-to-book ratio stands at 0.28, indicating that the market is valuing the company's equity at a fraction of its book value, which often suggests that the market does not expect significant growth or that the asset base is undervalued. Additionally, the price-to-sales ratio is 1.42 and the EV/EBITDA is -0.52, suggesting that investors are willing to pay a premium relative to revenue despite the negative earnings multiple, likely due to the potential growth in the non-invasive testing market. Price volatility is substantial, with the stock trading between a 52-week low of $2.50 and a 52-week high of $24.90, meaning the current price sits significantly below the 52-week high, reflecting recent market correction or lack of recent upward momentum. The beta value of 4.59 indicates that the stock price is approximately 3.59 times more volatile than the broader market, exposing investors to extreme price swings that could result from minor changes in sentiment regarding the medical device sector.
Growth & Income
Revenue growth year-over-year is recorded at 47.6%, while earnings growth is N/A due to the lack of profitable earnings in the trailing period, implying that top-line expansion is occurring without corresponding bottom-line improvement. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where earnings are theoretically reinvested into growth rather than distributed to shareholders, although current negative earnings limit the scope for such reinvestment. The overall growth and income profile is defined by rapid revenue expansion coupled with significant financial losses and a complete absence of dividend income for investors.